A 32-year-old woman from Mumbai presents on day 5 of fever with severe thrombocytopenia (platelets 20,000/μL), petechial rash, and spontaneous bleeding. Her friend, also infected with the same virus, presents on day 3 of fever with high fever, myalgia, and headache but normal platelet count and no bleeding manifestations. Which clinical feature best distinguishes dengue hemorrhagic fever (DHF) from dengue fever (DF)?

Explanation

## Distinguishing DHF from DF: The Critical Discriminator ### Pathophysiologic Basis The hallmark of dengue hemorrhagic fever is **plasma leakage** due to increased vascular permeability, which occurs during the critical phase (typically days 3–7 of illness). This leads to: - Hemoconcentration (elevated hematocrit ≥20% rise from baseline) - Thrombocytopenia (platelets <100,000/μL) - Hemorrhagic manifestations (petechiae, mucosal bleeding, GI bleeding) **Key Point:** DHF is defined by WHO criteria as dengue with: 1. Platelet count <100,000/μL AND 2. Evidence of plasma leakage (hemoconcentration, pleural effusion, ascites, hypoproteinemia) Dengue fever (DF) remains an uncomplicated febrile illness without these plasma leakage markers. ### Comparison Table: DF vs DHF | Feature | Dengue Fever (DF) | Dengue Hemorrhagic Fever (DHF) | |---------|------------------|--------------------------------| | **Platelet count** | Usually >100,000/μL | <100,000/μL | | **Hematocrit rise** | <20% | ≥20% (hemoconcentration) | | **Plasma leakage signs** | Absent | Present (effusions, ascites) | | **Hemorrhagic manifestations** | Absent or mild | Spontaneous bleeding, petechiae | | **Shock risk** | No | Yes (DHF Grade III–IV) | ### Clinical Timeline - **Day 1–3:** Both DF and DHF present with similar fever, myalgia, headache, rash - **Day 3–5 (Critical phase):** Plasma leakage becomes evident in DHF; DF remains uncomplicated - **Day 5–7:** Defervescence; DHF risk of dengue shock syndrome (DSS) **High-Yield:** The presence of **hemoconcentration + thrombocytopenia** is the single most discriminating feature that separates DHF from DF and triggers aggressive fluid management to prevent shock. **Clinical Pearl:** A patient with fever + rash + myalgia but normal platelets and no hemoconcentration is DF; the same patient with platelets <100,000/μL and hematocrit rise is DHF—a critical distinction that changes management from supportive care to careful fluid resuscitation and monitoring for shock. [cite:Harrison 21e Ch 189]